RxDoctor Payments Data

Laci Honeycutt, APRN

Family · Whitesburg, KYNPI 1104578616

Payments from drug & device makers

$817in general payments, 2019–2025

Across 41 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$147
  • AbbVie$112
  • Novo Nordisk$94
  • Otsuka America Pharmaceutical, Inc.$80
  • Grifols USA, LLC$56
  • Exact Sciences$43
  • plus $285 from 11 others

What the payments were for

  • Food & beverage$817100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$817 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$5,439
Medicare patients
50
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$83,678
OzempicSemaglutide31$28,211
JanuviaSitagliptin Phosphate28$24,917
JardianceEmpagliflozin19$23,939
EliquisApixaban30$22,893
FarxigaDapagliflozin Propanediol25$19,602
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$11,799
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,646
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl93$9,697
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,089
Gabapentin321$2,996
Pregabalin94$2,509
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,576
Ventolin HfaAlbuterol Sulfate28$1,569
Aripiprazole12$1,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$31$83,67878 claims
Novo NordiskOzempic$94$28,21131 claims
MerckJanuvia$37$24,91728 claims
AstraZenecaFarxiga$14$19,60225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Whitesburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →